Eddie Izzard, who recently completed 27 marathons in 27 days, will be performing at Nottingham Lakeside Arts with his show Force Majeure 333.

Not only will he be delivering his stand up show in three languages (German, French and English) but 25 per cent of ticket sales will be donated to Life Cycle 6 – the University’s annual fundraising campaign, raising funds for breast cancer research in Nottingham and Derby.

The campaign has a £1 million fundraising target and to help achieve this, the University is asking as many people as possible to join in fundraising activity – holding bake sales, charity events, sponsored walks and joining our community bike ride this September.

Professor Sir David Greenaway, the University’s Vice-Chancellor, is also leading a team of 13, taking on the challenge of a 1,400 sponsored bike ride to the four compass points of the UK.

Eddie first performed his 333 shows in Caen, Normandy, on the 70th anniversary of D-Day. He will be performing in Nottingham on Friday 20 May at 7pm in German, 8pm in French and 9pm in English.

Tickets are still available from Lakeside Arts for the French and German shows but have sold out for the English hour.

Lisa Johnson, one of four inspirational women with breast cancer supporting The University of Nottingham’s campaign, said: “To have Eddie Izzard offer his support through ticket sales is a huge boost. It’s such an important cause that affects so many women, so it’s great to receive this contribution to the campaign.

“Every day 140 women in the UK are told they have breast cancer. All funds raised in the campaign will go directly into laboratories to support world-leading breast cancer research at centres in Nottingham and Derby.”

Professors at the University, which has a long standing pedigree in breast cancer research, are working on innovative research to detect breast cancer early, stop it spreading and to develop targeted treatments that will help save lives.

Research includes developing the world’s first blood test to detect breast cancer early, stopping cancer from spreading around the body and developing targeted treatments – for both hormone sensitive cancers and triple negative breast cancer.